Adcirca (Tadalafil) for Pulmonary Hypertension | myPHteam

Connect with others who understand.

sign up Log in
About myPHteam
Powered By

Adcirca is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise in cases of pulmonary arterial hypertension. Adcirca may be referred to by its drug name, tadalafil.

Adcirca is a phosphodiesterase-5 (PDE-5) inhibitor. Adcirca inhibits the action of an enzyme called phosphodiesterase-5 (PDE-5), which works to control blood flow. In cases of pulmonary hypertension, Adcirca is believed to work by dilating the pulmonary arteries.

How do I take it?
Prescribing information states that Adcirca is taken once daily.

Adcirca comes in tablet form.

Side effects
The FDA-approved label for Adcirca lists common side effects including headache.
Rare but serious side effects listed for Adcirca include loss of vision, hearing impairment, and painful or prolonged erections.

For more details about this treatment, visit:

Adcirca — Lung Biotechnology

Phosphodiesterase 5 inhibitors — Pulmonary Hypertension Association UK

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in